Lobe Science在2025年改善了财务,削减了债务,提高了药物候选水平,减少了损失,尽管损失是净损失。 Lobe Sciences improved finances in 2025, cut debt, advanced drug candidates, and reduced losses despite a net loss.

Lobe Science公司报告说,2025财政年度的财务结果有所改善,现金增至585万美元,周转资金在2024年后期领导层大修开始后达到516万美元盈余。 Lobe Sciences reported improved financial results for fiscal year 2025, with cash rising to $5.85 million and working capital turning to a $5.16 million surplus after a leadership overhaul began in late 2024. 该公司取消了可兑换纸币,减少了衍生工具负债,并增加了169万美元的短期投资。 The company eliminated convertible notes, reduced derivative liabilities, and added $1.69 million in short-term investments. 尽管净损失486万美元,但每股损失减至0.03美元。 Despite a net loss of $4.86 million, the loss per share decreased to $0.03. 洛布研发了两种候选药物L-130用于慢性群头痛和物质使用障碍,以及S-100用于状细胞疾病使用基于脂质的输送平台. Lobe advanced two drug candidates—L-130 for chronic cluster headache and substance use disorder, and S-100 for sickle cell disease—using a lipid-based delivery platform. 它还依靠第三方补偿,对镰状细胞病人的医疗食品进行有限的商业化销售,尽管结果仍然不确定。 It also pursued limited commercialization of a medical food for sickle cell patients, relying on third-party reimbursement, though outcomes remain uncertain. 该公司旨在加强治理,减少负债,并通过研发创造价值,同时尽量减少股东稀释。 The company aims to strengthen governance, reduce liabilities, and create value through R&D while minimizing shareholder dilution.